A common polymorphism of the gene encoding acylcoenzyme A: cholesterol acyltransferase 1 (SOAT1), which is involved in the regulation of b-amyloid peptide generation, is associated with low brain amyloid load (P ¼ 0.03) and with low cerebrospinal fluid levels of cholesterol (P ¼ 0.005). This polymorphism of SOAT1 is also associated with reduced risk for Alzheimer's disease in ethnically distinct populations (P ¼ 0.0001, odds ratio: 0.6, 95% confidence interval 0.4-0.8).
A common polymorphism of the gene encoding acylcoenzyme A: cholesterol acyltransferase 1 (SOAT1), which is involved in the regulation of b-amyloid peptide generation, is associated with low brain amyloid load (P ¼ 0.03) and with low cerebrospinal fluid levels of cholesterol (P ¼ 0.005). This polymorphism of SOAT1 is also associated with reduced risk for Alzheimer's disease in ethnically distinct populations (P ¼ 0.0001, odds ratio: 0.6, 95% confidence interval 0. 4-0.8 Cholesterol regulates the production of the b-amyloid peptide (Ab), which is central to the pathogenesis of Alzheimer's disease (AD). 1 High cellular cholesterol promotes and low cellular cholesterol reduces Ab in vitro and in vivo. 2, 3 Acyl-coenzyme A: cholesterol acyltransferase 1 (ACAT1) esterifies cholesterol with long-chain fatty acids, and thereby controls the ratio of cellular free cholesterol and cholesterol esters. 4 Recently, Puglielli et al 5 demonstrated that functional deficiency or inhibition of ACAT1 in vitro leads to significant reduction of Ab. Thus, ACAT1-related intracellular compartmentation of cholesterol seems to be crucial for the generation of Ab.
5 SOAT1, the gene encoding ACAT1 maps to 1q25, a broad chromosomal region that is linked to AD in genome scans. 6, 7 Thus, SOAT1 is a positional candidate gene with high prior probability for association with the disease. 8 Here we provide clinical evidence supporting the relevance of ACAT1 in the pathophysiology of AD and in the regulation of Ab and cholesterol levels in the human CNS.
We conducted a genetic association study in 309 patients with sporadic AD according to the NINCDS-ADRDA criteria 9 and 356 healthy control subjects (HCS) from two ethnically and geographically distinct populations in central (Switzerland and Germany) and southern (Greece and Italy) Europe. Participants were genotyped for three common (ie frequency of the rare allele 410%) intragenic single-nucleotide polymorphisms (SNPs) in the 5 0 (rs1543876), central (rs2152318) and 3 0 (rs1044925) region of SOAT1. The allelic distribution of all three SNPs was that expected under Hardy-Weinberg equilibrium in AD patients and control subjects (P40.1). Rs1044925 was in strong, yet incomplete linkage disequilibrium (LD) with both rs2152318 (w 2 ¼ 70, df ¼ 1, most common haplotype: C-A) and rs1543876 (w 2 ¼ 147, df ¼ 1, most common haplotype: A-G). Rs2152318 and rs1543876 were in almost complete LD (w 2 ¼ 243, df ¼ 1, most common haplotype: C-G).
The A/A genotype of rs1044925 was significantly under-represented in AD patients (30.7% AD vs 44.1% HCS, P ¼ 0.0001, P ¼ 0.0007 after Bonferroni correction for testing three SNPs in SOAT1, APOE, allelic association, genotypic association, and association with age at onset) and was therefore associated with reduced risk for AD (OR ¼ 0.6, 95% CI ¼ 0.4-0.8) ( Table 1 ). Separate analysis in the two populations yielded similar results ( Table 1 ). The association of the A allele of rs1044925 with AD was less pronounced than the association of the AA genotype with the disease (Table 1) . Rs1044925 was not associated with age at onset of AD (P ¼ 0.92). Logistic regression analysis revealed that the protective effect of the A/A genotype was independent of gender, age, age at onset, and APOE. There was no association of rs2152318 (P ¼ 0.9) and rs1543876 (P ¼ 0.5) with AD. Estimated haplotypes between rs1044925 and rs2152318, as well as between rs1044925 and rs1543876 showed weaker association with AD than rs1044925 alone (P ¼ 0.019 and 0.037, respectively).
Since Ab production has been linked to cholesterol distribution and ACAT1 function, we tested whether the rs1044925 A/A genotype was also associated with brain b-amyloid load in humans. We assessed, by immunohistochemistry, the b-amyloid load in the medial temporal lobes of 58 elderly nondemented subjects by staging the expansion of Ab-deposition in the medial temporal lobe according to the phases described by Thal et al. 10, 11 The protective A/A genotype was specifically associated with low brain amyloid load (median for A/A: 0; median for non-A/ A: 2; P ¼ 0.030, Figure 1a ) and had no impact on Braak's neurofibrillary tangle (NFT) staging 12 (P ¼ 0.280).
To assess if rs1044925 was associated with CNS cholesterol homeostasis, we measured, by combined gas chromatography/mass spectrometry, 13 cholesterol as well as its precursors lathosterol and cholestanol and its catabolic derivative 24S-hydroxycholesterol in cerebrospinal fluid (CSF) of 22 healthy elderly subjects. We found significantly B40% lower levels of cholesterol in CSF of A/A carriers than in noncarriers (0.4670.17 vs 0.7670.26 mg/dl, P ¼ 0.005, Figure 1b) . Neither lathosterol nor cholestanol nor 24S-hydroxycholesterol were associated with the rs1044925 A/A genotype (P40.2). In line with the reported role of ACAT1, this difference may reflect genotype-specific changes in cholesterol distribution and compartmentation, rather than in cholesterol synthesis or clearance. The association of rs1044925 genotypes with CSF cholesterol was nonlinear (C/C 0.55 þ 0.33; C/A 0.85 þ 0.19; A/A 0.46 þ 0.18; P ¼ 0.023). In line with previous studies [14] [15] [16] , CSF levels of total cholesterol in AD patients (n ¼ 24) were lower than in healthy control subjects (n ¼ 22) (0.46 þ 0.14 vs 0.60 þ 0.26 mg/dl; P ¼ 0.040), but did not vary significantly with rs1044925 genotypes (A/A 0.53 þ 0.19, n ¼ 10; non-A/A 0.41 þ 0.08, n ¼ 14; P40.05).
We show that the A/A genotype of a common SOAT1 polymorphism is associated with low brain amyloid load and reduced risk for AD. Lack of ACAT1 activity reduces the production of Ab. 5 Therefore, our findings suggest that the A/A genotype of rs1044925 may be associated with reduced ACAT1 activity. In addition, we show that healthy carriers of the protective A/A genotype have low CSF cholesterol levels. Despite the complex relation between CSF and cellular cholesterol, low extracellular cholesterol levels may be indicative of reduced ACAT1 activity. Interestingly, deficiency of ACAT1 function in mice with disturbed cholesterol metabolism leads to low circulating cholesterol levels along with massive deposits of unesterified cholesterol. 17 Although the A/A genotype of rs1044925, which is located at the 3 0 UTR, may exert its protective effect through modification of mRNA stability, the possibility exists that our results may be explained through LD between rs1044925 and a causal SNP in SOAT1 or a nearby gene. However, we did not identify genes related to cholesterol metabolism within 1 cM of SOAT1. Thus, further study of possible LD should focus on SOAT1 and especially on the 3 0 region of the gene.
Our data support in vitro findings that suggest a role of ACAT1 in b-amyloid formation. We hypothesize that altered CNS cholesterol compartmentation associated with the SOAT1 A/A genotype may confer reduced formation of brain b-amyloid and thus reduce the risk for AD.
Methods
Patients and control subjects Two independent populations in central (Switzerland, Germany, n ¼ 301) and southern Europe (Greece, Italy, n ¼ 364) were included in genetic association studies. Clinical diagnosis of probable AD was made according to the NINCDS-ADRDA criteria, 9 based on medical interview, physical examination, neuropsychological testing, brain MRI, as well as blood and CSF tests. The mean Mini-Mental State Examination (MMSE) score of the patient population (n ¼ 309) was 19.5 þ 6.2, the mean age was 71.7 þ 7.8 years. The mean age at onset of AD was 68.4 þ 8.2 years. The control group (n ¼ 356) consisted of elderly individuals who were either the spouses of AD patients or subjects recruited from the outpatient clinics of the participating institutions. Dementia and memory deficits in control subjects were excluded by neuropsychological testing, consisting of the CERAD neuropsychological test battery and the MMSE. The mean age was 68.7 þ 8.6 years. The mean MMSE score was 29.1 þ 1.3.
The local Ethics Committee approved the study and informed consent was obtained prior to the investigation.
Genotyping
Leukocyte DNA was isolated using standard protocols (QIAamps DNA Blood Midi Kit, QIAGEN, Hilden, Germany). APOE genotyping was done as described by Hixson and Vernier. 18 Information on polymorphic sites of SOAT1 was derived from the database of single nucleotide polymorphisms (dbSNP) established by the National Center for Biotechnology Information (http: //www.ncbi.nlm.nih.gov/SNP/index.html). Genotyping for rs1044925 (C to A exchange at position 4439850 of contig NT_004487), rs2152318 (T to C exchange at position 4409623 of contig NT_004487.12), and rs1543876 (A to G exchange at position 4395922 of contig NT_004487.12) was done with the Masscode TM system. 19 A subset of samples was genotyped for rs1044925 by pyrosequencing CSF cholesterol measurement CSF was obtained by lumbar puncture in a subset of the participants of the genetic studies in Zurich. In all, 22 healthy elderly subjects (mean age: 65.6 years) and 24 AD patients (mean age: 71.0 years) were included. CSF cholesterol, lathosterol, cholestanol, and 24S-hydroxycholesterol were measured by means of combined gas chromatography/mass spectrometry. 13 Neuropathology Neuropathological examinations were performed in the brains of 58 elderly nondemented individuals (mean age of death: 72.378.5 years, range 60-91 years, 25 females, 32 males) from the central European sample. Antemortem clinical examinations confirmed absence of dementia as measured by the Clinical Dementia Rating (CDR) scale (CDR-score: 0). DNA was extracted from the respective freshly frozen brain. For neuropathology, formalin-fixed, paraffinand/or polyethylene-glycol-embedded tissue sections of the medial temporal lobe were stained with hematoxylin-Eosin or with the aldehydfuchsin-Darrow-red stain. Ab-deposits were detected by immunohistochemistry with an antibody raised against the Ab 17-24 -peptide (4G8, Signet) and by the use of the Campbell-Switzer silver technique. The evolutionary phases (0-4) of b-amyloid load in the medial temporal lobes of these subjects were determined as described by Thal et al. 10, 11 Staging for neurofibrillary changes (NFT-staging) was performed according to Braak and Braak. 12 Statistical analyses Genotype and allele frequencies between AD patients and control subjects were compared by Fisher's exact tests. Forward and backward unconditional logistic regression analyses were done for the simultaneous assessment of the influence of age, gender, APOE, and SOAT1 genotypes on the risk for AD. Testing for LD between the studied SNPs was performed by the estimate haplotype frequencies (EH) program. 20 Analysis of differences in CSF cholesterol concentrations between disease and genotype groups was done by ttests or by ANOVA. Statistical significance was assumed at Pr0.05.
